-
1.
公开(公告)号:US20180079707A1
公开(公告)日:2018-03-22
申请号:US15424341
申请日:2017-02-23
发明人: Thibaud PORTAL
IPC分类号: C07C65/19 , C07D213/80
CPC分类号: C07C65/19 , A61K8/368 , A61Q19/00 , A61Q19/08 , C07C2601/14 , C07C2602/10 , C07D213/80
摘要: The invention relates to new compounds of the general formula (I): as well as the use thereof in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, in particular), or in the use of cosmetic compositions.
-
2.
公开(公告)号:US20190337881A1
公开(公告)日:2019-11-07
申请号:US16075592
申请日:2017-02-03
发明人: Thibaud PORTAL
IPC分类号: C07C65/19 , C07D213/80 , A61K8/368 , A61K8/49 , A61Q19/00
摘要: Compounds of general formula (I) are described. Also described, is the use of such compounds in pharmaceutical compositions for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmologic disorders, in particular), or in cosmetic compositions.
-
3.
公开(公告)号:US20170342040A1
公开(公告)日:2017-11-30
申请号:US15537549
申请日:2015-12-17
发明人: Thibaud PORTAL
IPC分类号: C07D277/30 , C07D271/06 , C07D261/08 , C07D271/107 , C07D231/12
CPC分类号: C07D277/30 , A61K8/49 , A61K8/4913 , A61K8/494 , A61K8/4986 , A61K2800/522 , A61Q5/008 , A61Q7/00 , A61Q19/00 , A61Q19/007 , A61Q19/008 , A61Q19/08 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D261/08 , C07D263/32 , C07D271/06 , C07D271/10 , C07D271/107 , C07D285/12 , C07D333/24
摘要: Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.
-
4.
公开(公告)号:US20150297517A1
公开(公告)日:2015-10-22
申请号:US14693361
申请日:2015-04-22
发明人: Thibaud PORTAL
IPC分类号: A61K9/107 , A61K47/32 , A61K31/245 , A61K45/06 , A61K31/498 , A61K31/167
CPC分类号: A61K9/107 , A61K9/0014 , A61K31/167 , A61K31/245 , A61K31/45 , A61K31/498 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/32 , A61K2300/00
摘要: A composition is described with reduced degradation rate and/or improved stability of its components. The composition can alleviate or even annihilate cutaneous reactions and can include an emulsion with an oil phase and an aqueous phase, wherein the oil phase can be a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist. Methods of using such a composition are also described.
摘要翻译: 描述了具有降低的降解速率和/或其组分的改进的稳定性的组合物。 组合物可以减轻或甚至消除皮肤反应,并且可以包括具有油相和水相的乳液,其中油相可以是至少一种麻醉化合物和至少一种肾上腺素能受体激动剂的共晶混合物。 还描述了使用这种组合物的方法。
-
-
-